Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PCMA Hires Public Affairs Specialists For PBM “Campaign” Lobbying Strategy

Executive Summary

The Pharmaceutical Care Management Association has hired two public affairs specialists as part of its effort to bring a "campaign" style of promoting pharmacy benefit management companies in Washington, D.C

You may also be interested in...



USP To Help Set Formulary Rules Under Medicare Rx Bill

The U.S. Pharmacopeia would play a central role in setting the ground rules for formularies under the Medicare prescription drug bill

USP To Help Set Formulary Rules Under Medicare Rx Bill

The U.S. Pharmacopeia would play a central role in setting the ground rules for formularies under the Medicare prescription drug bill

Formularies Would Be Authorized But Restricted Under Senate Medicare Bill

The Senate Finance Medicare drug coverage bill includes language dictating that beneficiaries cannot be forced to pay a higher copay for a non-formulary product if it is determined to be medically necessary

Related Content

UsernamePublicRestriction

Register

PS041821

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel